Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

1.0K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
1.0K
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

215
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
215
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

332
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
332
Regulated mRNA Transport02:22

Regulated mRNA Transport

7.0K
In eukaryotes, transcription and translation are compartmentalized; an mRNA is first synthesized in the nucleus and then selectively transported to the cytoplasm for protein synthesis. Before transport, a pre-mRNA undergoes several steps of post-transcriptional modifications including splicing, 5' capping, and the addition of a poly-adenine tail. Various proteins bind to the pre-mRNA during these modifications. The mRNA transport takes place with the help of multiple proteins playing...
7.0K
Nuclear Export of mRNA02:31

Nuclear Export of mRNA

8.8K
Before mRNAs are exported to the cytoplasm, it is crucial to check each mRNA for structural and functional integrity. Eukaryotic cells use several different mechanisms, collectively known as mRNA surveillance, to look for irregularities in mRNAs. Irregular or aberrant mRNA are rapidly degraded by various enzymes. If a defective mRNA escapes the surveillance, it would be translated into a protein which would either be non-functional or not function properly. One of the primary irregularities in...
8.8K
pre-mRNA Processing02:01

pre-mRNA Processing

57.5K
In eukaryotic cells, transcripts made by RNA polymerase are modified and processed before exiting the nucleus. Unprocessed RNA is called precursor mRNA or pre-mRNA to distinguish it from mature mRNA.
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl...
57.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reprogramming the diseased liver: antioxidant-engineered mRNA nanoparticles as microenvironment modulators in MAFLD.

Immunometabolism (Cobham, Surrey)·2026
Same author

Influenza hijacks myeloid cells to inflict type-I interferon-fueled damage in the heart.

Immunity·2026
Same author

A Systemic Selective Modified mRNA Delivery Platform for Preventing Chemotherapy-Induced Cardiotoxicity.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Transient overexpression of hPKM2 in porcine cardiomyocytes prevents heart failure after myocardial infarction.

Nature communications·2025
Same author

A tumor-selective mRNA system enables precision cancer treatment.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Pyruvate Kinase M2 Role in Cardiovascular Repair.

Cells·2025

Related Experiment Video

Updated: Jan 31, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.3K

mRNA-Based Protein Replacement Therapy for the Heart.

Ajit Magadum1, Keerat Kaur1, Lior Zangi1

  • 1Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|January 7, 2019
PubMed
Summary

Modified mRNA (modRNA) offers a promising, safe, and effective alternative to gene therapy for heart attack and heart failure treatment. This approach can potentially regenerate heart tissue after myocardial infarction, overcoming previous delivery challenges.

Keywords:
cardiac regenerationgene therapymRNA therapy

More Related Videos

An Oligonucleotide-based Tandem RNA Isolation Procedure to Recover Eukaryotic mRNA-Protein Complexes
09:45

An Oligonucleotide-based Tandem RNA Isolation Procedure to Recover Eukaryotic mRNA-Protein Complexes

Published on: August 18, 2018

11.6K
Cell Based Assays of SINEUP Non-coding RNAs That Can Specifically Enhance mRNA Translation
10:21

Cell Based Assays of SINEUP Non-coding RNAs That Can Specifically Enhance mRNA Translation

Published on: February 1, 2019

8.8K

Related Experiment Videos

Last Updated: Jan 31, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.3K
An Oligonucleotide-based Tandem RNA Isolation Procedure to Recover Eukaryotic mRNA-Protein Complexes
09:45

An Oligonucleotide-based Tandem RNA Isolation Procedure to Recover Eukaryotic mRNA-Protein Complexes

Published on: August 18, 2018

11.6K
Cell Based Assays of SINEUP Non-coding RNAs That Can Specifically Enhance mRNA Translation
10:21

Cell Based Assays of SINEUP Non-coding RNAs That Can Specifically Enhance mRNA Translation

Published on: February 1, 2019

8.8K

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Molecular Therapy

Background:

  • Myocardial infarction (MI) and heart failure (HF) are leading causes of death globally.
  • Loss of cardiomyocytes post-MI leads to scarring and HF due to limited adult mammalian heart regeneration.
  • Current treatments for cardiac regeneration are lacking, with gene therapy facing delivery challenges.

Purpose of the Study:

  • To review the potential of modified mRNA (modRNA) in cardiac therapy for cardioprotection and regeneration post-MI.
  • To evaluate modRNA as a safer and more effective alternative to DNA-based or viral gene therapy for cardiac conditions.
  • To discuss challenges and future directions for modRNA application in treating ischemic heart disease.

Main Methods:

  • Review of existing literature on modRNA technology and its application in cardiac regeneration.
  • Analysis of modRNA's properties (safety, efficiency, transient nature) for cardiac gene delivery.
  • Discussion of challenges in current modRNA-based cardiac treatment strategies.

Main Results:

  • Modified mRNA (modRNA) presents a safe, non-immunogenic, and efficient nucleic acid delivery system.
  • modRNA can overcome the limitations of poor and uncontrolled gene delivery associated with viral and DNA-based methods.
  • modRNA holds potential for inducing cardioprotection and promoting vascular or cardiac regeneration after MI.

Conclusions:

  • modRNA technology offers a promising therapeutic strategy for myocardial infarction and heart failure.
  • Further research is needed to address current challenges for successful clinical application of modRNA in ischemic heart disease.
  • modRNA represents a significant advancement in regenerative medicine for cardiovascular diseases.